Synonyms: ATN-103 | PF-5230896
Compound class:
Antibody
Comment: Ozoralizumab is a trivalent albumin-binding nanobody that binds to and neutralises circulating TNFα. This biologic agent is being investigated for anti-inflammatory potential. The peptide sequence for ozoralizumab submitted in its WHO INN record is identical to SEQ ID NO: 96 (TNF30) in patent US8703131 [1], and identifies the albumin nanobody as ALB8. The patent claims a trivalent construct of TNF30-linker-ALB8-linker-TNF30.
|
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
9369 | ozoralizumab |
Synonyms ![]() |
ATN-103 | PF-5230896 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 382 |
Other databases | |
GtoPdb PubChem SID | 340590268 |
Search PubMed clinical trials | ozoralizumab |
Search PubMed titles | ozoralizumab |
Search PubMed titles/abstracts | ozoralizumab |